Abstracts (Missouri Technology Expo 2010)

Permanent URI for this collection

https://hdl.handle.net/10355/9637

This collection contains the abstracts for the posters and elevator pitch sessions of the Missouri Technology Expo 2010. Please enter text in the search box above or click on one of the browse options to explore this collection.

Browse

Recent Submissions

Now showing 1 - 5 of 56
  • No Thumbnail Available
    Item
    Wound care [abstract]
    (2010-10) Day, Delbert E.; Jung, Steven; Missouri Technology Expo
    The invention can be used as a wound care material for treating both hard and soft tissues in mammals. Wounds such as diabetic ulcers or other open wounds can be covered with this bioactive and biodegradable material to form a temporary and resorbable barrier while providing useful materials to promote the wound healing process. This bioactive material can be made into a variety of shapes and forms for applications ranging from wound covering to implant fixation. Potential Areas of Applications: * Flexible dressing for wound care management comprising a three-dimensional compressible body of loose glass-based fibers * Can also be formed into rigid material for implantation * Can be combined with other materials to promote healing * Can be formulated as biocompatible surgical glue for closing a wound * Material can be compounded to contain trace elements to promote bone, vessel and tissue growth
  • No Thumbnail Available
    Item
    Two novel biomarkers for early diagnosis of renal cell carcinoma [abstract]
    (2010-10) Kharasch, Evan D.; Missouri Technology Expo
    Urinary aquaporin-I (AQP-1) and adipose differentiation-related protein (ADFP) as biomarkers of kidney cancer. This is a new process, applicable to humans, for 1) early and noninvasive detection of renal cancer, 2) population screening for renal cancer, 3) post-treatment surveillance for recurrence of renal cancer, 4) progression, regression or time-course of disease in untreated, partially treated, and definitively treated patients with renal cancer. The process is noninvasive, using readily available biological fluids such as urine and possibly blood. The proteins AQP-2 and ADFP are over-expressed in renal cancer tissue. These proteins may be shed into urine. The invention, per se, is a method (Western blot analysis or ELISA) for the sensitive detection and quantification of AQP-2 and ADFP in human urine, a readily available biological fluid, and the application of this assay for the detection and diagnosis of renal cancer, population screening for kidney cancer, surveillance for recurrence following or during treatment, and determining success of treatment and assessment of prognosis. Potential Areas of Applications: * Oncology * Markers Patent Status: Pending Inventor(s): Evan Kharasch, MD, PhD Contact Info: Jon Kratochvil, Esq. kratochj@wustl.edu (314) 747-0923
  • No Thumbnail Available
    Item
    Treatment of cardiovascular risk factors, nitric oxide synthesis, and c-reactive protein using a combination therapy of vitamins and flavanoids [abstract]
    (2010-10) Qureshi, Asaf A.; Qureshi, Nilofer; Papasian, Christopher J.; Reis, Julia C.; Morrison, David C., 1941-; Missouri Technology Expo
    Researchers at the University of Missouri Kansas City have studied the synergistic effects of a novel combination of vitamins and flavanoids on cardiovascular risk factors, C-reactive protein levels, and nitric oxide production in the human body. Clinical trial results showed a marked decrease in the patients' serum nitric oxide and C-reactive protein levels. In addition, Hypercholesterolemic human subjects showed significant reductions in their lipid parameters (except for HDL cholesterol), and all subjects showed increases in total antioxidant status. Potential Areas of Applications: * Use as a nutritional supplement
  • No Thumbnail Available
    Item
    Thomsen-Friedenreich (TF) antigen in nipple aspirate fluid: biomarker for breast cancer detection
    (2010-10) Quinn, Thomas P. (Thomas Patrick), 1961-; Deutscher, Susan L.; Sauter, Edward R.; Missouri Technology Expo
    Early detection and diagnosis are critical to successful treatment of breast cancer. Currently available breast cancer screening tools such as mammography and breast examination miss up to 40% of early breast cancers, are least effective in detecting cancer in young women whose tumors are often more aggressive, and require that an invasive needle or surgical biopsy be performed when an area of suspicion is identified to confirm the presence of malignancy. Over a million surgical or needle breast biopsies will be performed this year to diagnose 203,000 new breast cancers. Using current techniques, women will undergo 5 diagnostic biopsies to diagnose each new cancer, and each biopsy is painful, invasive and expensive. The current invention developed by researchers at the University of Missouri analyses nipple aspirate fluid (NAF) for predictive biomarkers of breast cancer. One such biomarker is the Thomsen-Friedenreich (TF) glycoantigen, which is over-expressed on the majority of breast cancer cells. NAF can be obtained non invasively and contains a small number of cancer cells, but relatively high levels of proteins and lipids. We have developed and tested in a clinical study a simple and sensitive immuno-assay for identifying the cancer-associated TF and Tn biomarkers in NAF. Antigen detection and NAF collection are inexpensive procedures, involving commercially available reagents, insuring that the procedures could be rapidly translated to the clinic upon validation. Potential Areas of Applications: * Screening for and managing breast cancer
  • No Thumbnail Available
    Item
    Targeted antisense radiotherapy [abstract]
    (2010-10) Lewis, Michael R.; Balkin, Ethan; Missouri Technology Expo
    Cancer is the one of the leading causes of death worldwide. While huge strides have been made in the treatment of various cancers, there is still a critical need for effective therapeutics that only target and kill the cancer cells while not affecting other cells in the body. The current invention developed by researchers at the University of Missouri is a novel agent for simultaneous, targeted gene and radiation therapy of blood cancers. The agent binds selectively to non-Hodgkin's lymphoma (NHL) cells and contains an antisense module that reduces the activity of a cancer gene to sensitize tumors to radiation. Simultaneously, the agent delivers radiation that is highly efficient at killing these sensitized cancer cells. Our invention is superior to conventional targeted radiotherapy because its two simultaneous mechanisms of action work together to ensure better cancer cell killing, potentially giving it more efficacy than existing approaches. Potential Areas of Applications: * Treatment of blood cancer * Can be modified to treat other cancers Patent Status: Provisional patent application cover sheet on file - 10UMC069prov Inventor(s): Michael Lewis, Ethan Balkin Contact Info: Harriet F. Francis, MS; J.D. francish@missouri.edu 573-884-0374 Per Stromhaug, Ph.D., MBA stromhaugpe@missouri.edu 573-884-3553

Items in MOspace are protected by copyright, with all rights reserved, unless otherwise indicated.